|
|
Profile
|
Delegates :
Yukie Yoshii |
|
Incorporated :
July 4 , 2022 |
Paid in Capital :
30 Million yen |
Employees :
20 人 |
Address :
2-10-24 Ohnodai, Midori-ku, 2 Chiba-shi CHIBA
〒267-0056
|
TEL/FAX :
+81-3-6661-7661 / |
URL：
https://linqmed.co.jp/en/ |
Attachment :
|
Mission/Background :
LinqMed Inc. is a Japan-based radiopharmaceutical company founded in 2022. The company develops next-generation radiopharmaceuticals using Copper-64 (64Cu) and aims to realize innovative "Visible Cancer Therapy," integrating diagnosis and treatment into a single platform. LinqMed seeks to deliver personalized cancer care and establish a domestic radiopharmaceutical manufacturing ecosystem. |
|
Technology & Business
|
LinqMed develops theranostic radiopharmaceuticals utilizing Copper-64, which enables both PET imaging and targeted radiotherapy. Its lead program, LM001 (64Cu-ATSM), targets recurrent and refractory malignant gliomas. The company also develops 64Cu production technologies and manufacturing infrastructure to accelerate radiopharmaceutical development in Japan.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
LM001 (64Cu-ATSM)
|
Phase3
|
Radiotherapeutic for recurrent malignant glioma
|
Regulatory approval and launch
|
Radiolabeled Antibody Imaging Program
|
Phase1
|
Antibody-based molecular imaging agents
|
Clinical development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
LinqMed completed its state-of-the-art Chiba manufacturing facility for Copper-64 and radiopharmaceutical production. The company continues clinical development of LM001 and advances its 64Cu drug discovery platform under support from the NEDO Deep-Tech Startup Program. Additionally, Including the first close, the total amount raised in Series B has reached \3.55 billion, bringing the company’s cumulative fundraising total to approximately \4.7 billion.
|
|
Hot news
|
LinqMed is seeking strategic partners for co-development, licensing, manufacturing collaboration, and global commercialization of 64Cu-based radiopharmaceuticals. The company welcomes partnerships with pharmaceutical companies, research institutes, hospitals, and biotech firms interested in theranostics and oncology.
|
|
Alliance strategy
|
LinqMed is seeking strategic partners for co-development, licensing, manufacturing collaboration, and global commercialization of 64Cu-based radiopharmaceuticals. The company welcomes partnerships with pharmaceutical companies, research institutes, hospitals, and biotech firms interested in theranostics and oncology.
|
|
|